These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22259238)

  • 21. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.
    Ritchie CW; Chiu E; Harrigan S; Hall K; Hassett A; Macfarlane S; Mastwyk M; O'Connor DW; Opie J; Ames D
    Int J Geriatr Psychiatry; 2003 May; 18(5):432-40. PubMed ID: 12766921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.
    Ascher-Svanum H; Nyhuis AW; Stauffer V; Kinon BJ; Faries DE; Phillips GA; Schuh K; Awad AG; Keefe R; Naber D
    Curr Med Res Opin; 2010 Oct; 26(10):2403-10. PubMed ID: 20812791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients.
    Bobes J; Gibert J; Ciudad A; Alvarez E; Cañas F; Carrasco JL; Gascón J; Gómez JC; Gutiérrez M
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):473-81. PubMed ID: 12691783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: a multivariate analysis of a large naturalistic study in the hospital setting.
    Cañas F; Ciudad A; Gutiérrez M; Gibert J; Gascón J; Carrasco JL; Bobes J; Gómez JC; Alvarez E
    Med Clin (Barc); 2005 Apr; 124(13):481-6. PubMed ID: 15847764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
    Haro JM; Novick D; Suarez D; Roca M
    J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F; Schreiner A; Thomas P; Sherif T
    Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
    Zhu B; Ascher-Svanum H; Faries DE; Correll CU; Kane JM
    BMC Psychiatry; 2008 Apr; 8():19. PubMed ID: 18394168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis.
    Ye W; Ascher-Svanum H; Tanji Y; Flynn JA; Takahashi M; Conley RR
    Neuropsychiatr Dis Treat; 2012; 8():259-66. PubMed ID: 22745559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with early response to olanzapine and clinical and functional outcomes of early responders treated for schizophrenia in the People's Republic of China.
    Ye W; Montgomery W; Kadziola Z; Liu L; Xue H; Stensland MD; Treuer T
    Neuropsychiatr Dis Treat; 2014; 10():869-78. PubMed ID: 24876779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia.
    Lee C; Wu KH; Habil H; Dyachkova Y; Lee P
    Aust N Z J Psychiatry; 2006 May; 40(5):437-45. PubMed ID: 16683970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study.
    Alvarez E; Bobes J; Gómez JC; Sacristán JA; Cañas F; Carrasco JL; Gascón J; Gibert J; Gutiérrez M;
    Eur Neuropsychopharmacol; 2003 Jan; 13(1):39-48. PubMed ID: 12480121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up.
    Karagianis JL; LeDrew KK; Walker DJ
    Curr Med Res Opin; 2003; 19(6):473-80. PubMed ID: 14594518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.
    Gasquet I; Haro JM; Novick D; Edgell ET; Kennedy L; Lepine JP;
    Int Clin Psychopharmacol; 2005 Jul; 20(4):199-205. PubMed ID: 15933480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.
    Kemp DE; Correll CU; Tohen M; Delbello MP; Ganocy SJ; Findling RL; Chang K
    J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):522-30. PubMed ID: 24111982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study.
    Montes JM; Ciudad A; Gascón J; Gómez JC;
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):667-74. PubMed ID: 12787855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of severely psychotic inpatients with schizophrenia: olanzapine versus other antipsychotic drugs.
    Carrasco JL; Gutiérrez M; Gómez JC; Escobar R; Alvarez E; Cañas F; Bobes J; Gascón J; Gibert J
    Int Clin Psychopharmacol; 2002 Nov; 17(6):287-95. PubMed ID: 12409682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study.
    Rodríguez-Pérez V; López A; Blanco C; Peña C; López A; Abel A; Gómez Y; Ferreiro MJ; Rego C; López A; Cudeiro F; Alvarez V; Prieto R; Ciudad A
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Oct; 26(6):1055-62. PubMed ID: 12452526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.